RenovoRx TIGeR-PaC Trial Enrollment on Track for 2026 Completion
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 26 2026
0mins
Source: Newsfilter
- Trial Milestone Achieved: RenovoRx has surpassed 100 randomized patients in its TIGeR-PaC clinical trial, remaining on track for enrollment completion in the first half of 2026, with final data expected in 2027, demonstrating the company's ongoing commitment and innovation in cancer treatment.
- Device Application Expansion: Select TIGeR-PaC cancer centers have begun using RenovoCath® as a stand-alone device for drug delivery in oncology management, which not only enhances treatment precision but may also improve patient outcomes and experiences.
- Clinical Trial Design: The TIGeR-PaC trial protocol requires 114 randomized patients and 86 events for final analysis; currently, 104 patients have been randomized with 72 events recorded, ensuring the statistical validity and scientific rigor of the trial.
- Market Potential: RenovoRx's IAG product candidate is under FDA evaluation, and if approved, it will provide new treatment options for pancreatic and bile duct cancer patients, representing significant market potential and societal value.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RNXT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RNXT
Wall Street analysts forecast RNXT stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.844
Low
3.00
Averages
5.63
High
12.50
Current: 0.844
Low
3.00
Averages
5.63
High
12.50
About RNXT
RenovoRx, Inc. is a clinical and a commercial biopharmaceutical company. Its lead product RenovoCath a local drug delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents. In addition to the RenovoCath device, RenovoRx is also evaluating the novel Phase III drug-device combination oncology product candidate (intra-arterial gemcitabine, known as IAG). The combination of intra-arterial infusion of chemotherapy, gemcitabine, and the RenovoCath device is being evaluated for the treatment of locally advanced pancreatic cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
RenovoRx Publishes Case Study on Pancreatic Cancer Treatment
- Case Study Publication: RenovoRx announced the publication of a peer-reviewed case study from Moffitt Cancer Center researchers, highlighting the optimization potential of the TAMP procedure using RenovoCath, which may transform pancreatic cancer treatment.
- Significant Treatment Outcomes: The case study revealed a 52% reduction in tumor metabolic activity on PET-CT imaging after eight TAMP treatments, indicating the method's effectiveness in monitoring therapeutic response and offering new hope for patients with difficult-to-treat cancers.
- Innovative Technology Application: The study successfully employed coil and glue embolization of a pancreaticoduodenal artery side branch to optimize RenovoCath's application in TAMP, demonstrating the technology's flexibility and efficacy in addressing complex anatomical challenges.
- Commercialization Progress: RenovoRx achieved approximately $1.1 million in RenovoCath sales in 2025 and set a record of $563,000 in the first quarter of 2026, showcasing its market potential and growth prospects in the oncology treatment sector.
See More
RenovoRx CEO to Present at Investment Conference
- Performance Highlight: RenovoRx achieved a record $563,000 in sales during Q1 2026, reflecting strong demand for RenovoCath as a standalone drug delivery device, which is expected to further drive revenue growth for the company.
- Clinical Trial Progress: The company anticipates completing enrollment in its Phase III TIGeR-PaC clinical trial by the end of June 2026, marking a significant milestone that will provide critical data for evaluating treatment efficacy in locally advanced pancreatic cancer, with final results expected in mid-to-late 2027.
- FDA Designation and Market Exclusivity: RenovoRx recently received FDA Orphan Drug Designation for oxaliplatin for pancreatic cancer treatment, which will grant seven years of market exclusivity upon approval, further solidifying its position in the oncology market.
- Investor Conference Details: CEO Shaun Bagai will present at the iAccess Alpha Virtual Investment Conference on June 23, 2026, discussing the company's latest developments and future strategies, thereby enhancing investor confidence in RenovoRx.
See More
RenovoRx Receives FDA Orphan Drug Designation for Oxaliplatin
- Orphan Drug Designation: RenovoRx announced that its oxaliplatin for pancreatic cancer has received FDA Orphan Drug Designation, marking the company's second designation in this area and highlighting its unique advantages in targeted drug delivery.
- Innovative Drug Delivery: The company employs its RenovoCath device for targeted intra-arterial drug delivery, having secured three orphan drug designations, which underscores its flexibility and innovation in delivering multiple therapeutic agents directly to tumor sites.
- Market Expansion: RenovoRx is advancing the commercialization of RenovoCath as a stand-alone device, aiming to drive adoption at leading cancer centers, thereby enhancing its competitive position in the market.
- Stock Price Movement: In Thursday's pre-market trading, RNXT was priced at $0.93, down $0.005 or 0.53%, reflecting a cautious market sentiment regarding the company's latest developments.
See More
RenovoRx Receives FDA Orphan Drug Designation
- FDA Orphan Drug Designation: RenovoRx has received Orphan Drug Designation from the FDA for oxaliplatin in treating pancreatic cancer, marking a significant recognition of the company's targeted drug delivery approach, which is expected to enhance its market competitiveness and investment appeal.
- Market Exclusivity Rights: Upon FDA approval of the indication, RenovoRx will enjoy seven years of market exclusivity, providing a stable revenue stream and strengthening its position in the oncology treatment market.
- Clinical Trial Progress: RenovoRx's TIGeR-PaC Phase III clinical trial is ongoing, with enrollment expected to close in June 2026 and final data readout anticipated in mid to late 2027, further validating its therapeutic efficacy.
- Sales Growth Potential: In 2025, RenovoRx generated approximately $1.1 million in RenovoCath sales, with a record $563,000 in the first quarter of 2026, indicating increasing market acceptance and future growth potential for its products.
See More
RenovoRx (RNXT) Q1 2026 Earnings Transcript
See More
RenovoRx CEO to Participate in Healthcare Showcase
- Commercial Progress Highlight: RenovoRx achieved record sales of $563,000 in Q1 2026 from RenovoCath as a standalone drug-delivery device, indicating strong demand and growth potential in the oncology market.
- Clinical Trial Advancement: The ongoing Phase III TIGeR-PaC trial is expected to complete enrollment by June 2026, providing critical data for evaluating the efficacy of the novel drug-device combination in locally advanced pancreatic cancer, which may drive future market applications.
- Research Support Initiatives: RenovoRx is actively supporting investigator-initiated trials for borderline resectable and metastatic pancreatic cancer, which not only provide valuable data for the TAMP therapy platform but also potentially broaden its clinical application and enhance market competitiveness.
- Showcase Participation: CEO Shaun Bagai and CFO Mark Voll will participate in the AGP Annual Healthcare Company Showcase on May 20, 2026, discussing the company's commercial progress and clinical research, which is expected to attract investor interest and enhance the company's visibility.
See More
RenovoRx Publishes Case Study on Pancreatic Cancer Treatment
- Case Study Publication: RenovoRx announced the publication of a peer-reviewed case study from Moffitt Cancer Center researchers, highlighting the optimization potential of the TAMP procedure using RenovoCath, which may transform pancreatic cancer treatment.
- Significant Treatment Outcomes: The case study revealed a 52% reduction in tumor metabolic activity on PET-CT imaging after eight TAMP treatments, indicating the method's effectiveness in monitoring therapeutic response and offering new hope for patients with difficult-to-treat cancers.
- Innovative Technology Application: The study successfully employed coil and glue embolization of a pancreaticoduodenal artery side branch to optimize RenovoCath's application in TAMP, demonstrating the technology's flexibility and efficacy in addressing complex anatomical challenges.
- Commercialization Progress: RenovoRx achieved approximately $1.1 million in RenovoCath sales in 2025 and set a record of $563,000 in the first quarter of 2026, showcasing its market potential and growth prospects in the oncology treatment sector.
See More
RenovoRx CEO to Present at Investment Conference
- Performance Highlight: RenovoRx achieved a record $563,000 in sales during Q1 2026, reflecting strong demand for RenovoCath as a standalone drug delivery device, which is expected to further drive revenue growth for the company.
- Clinical Trial Progress: The company anticipates completing enrollment in its Phase III TIGeR-PaC clinical trial by the end of June 2026, marking a significant milestone that will provide critical data for evaluating treatment efficacy in locally advanced pancreatic cancer, with final results expected in mid-to-late 2027.
- FDA Designation and Market Exclusivity: RenovoRx recently received FDA Orphan Drug Designation for oxaliplatin for pancreatic cancer treatment, which will grant seven years of market exclusivity upon approval, further solidifying its position in the oncology market.
- Investor Conference Details: CEO Shaun Bagai will present at the iAccess Alpha Virtual Investment Conference on June 23, 2026, discussing the company's latest developments and future strategies, thereby enhancing investor confidence in RenovoRx.
See More
RenovoRx Receives FDA Orphan Drug Designation for Oxaliplatin
- Orphan Drug Designation: RenovoRx announced that its oxaliplatin for pancreatic cancer has received FDA Orphan Drug Designation, marking the company's second designation in this area and highlighting its unique advantages in targeted drug delivery.
- Innovative Drug Delivery: The company employs its RenovoCath device for targeted intra-arterial drug delivery, having secured three orphan drug designations, which underscores its flexibility and innovation in delivering multiple therapeutic agents directly to tumor sites.
- Market Expansion: RenovoRx is advancing the commercialization of RenovoCath as a stand-alone device, aiming to drive adoption at leading cancer centers, thereby enhancing its competitive position in the market.
- Stock Price Movement: In Thursday's pre-market trading, RNXT was priced at $0.93, down $0.005 or 0.53%, reflecting a cautious market sentiment regarding the company's latest developments.
See More
RenovoRx Receives FDA Orphan Drug Designation
- FDA Orphan Drug Designation: RenovoRx has received Orphan Drug Designation from the FDA for oxaliplatin in treating pancreatic cancer, marking a significant recognition of the company's targeted drug delivery approach, which is expected to enhance its market competitiveness and investment appeal.
- Market Exclusivity Rights: Upon FDA approval of the indication, RenovoRx will enjoy seven years of market exclusivity, providing a stable revenue stream and strengthening its position in the oncology treatment market.
- Clinical Trial Progress: RenovoRx's TIGeR-PaC Phase III clinical trial is ongoing, with enrollment expected to close in June 2026 and final data readout anticipated in mid to late 2027, further validating its therapeutic efficacy.
- Sales Growth Potential: In 2025, RenovoRx generated approximately $1.1 million in RenovoCath sales, with a record $563,000 in the first quarter of 2026, indicating increasing market acceptance and future growth potential for its products.
See More
RenovoRx (RNXT) Q1 2026 Earnings Transcript
See More
RenovoRx CEO to Participate in Healthcare Showcase
- Commercial Progress Highlight: RenovoRx achieved record sales of $563,000 in Q1 2026 from RenovoCath as a standalone drug-delivery device, indicating strong demand and growth potential in the oncology market.
- Clinical Trial Advancement: The ongoing Phase III TIGeR-PaC trial is expected to complete enrollment by June 2026, providing critical data for evaluating the efficacy of the novel drug-device combination in locally advanced pancreatic cancer, which may drive future market applications.
- Research Support Initiatives: RenovoRx is actively supporting investigator-initiated trials for borderline resectable and metastatic pancreatic cancer, which not only provide valuable data for the TAMP therapy platform but also potentially broaden its clinical application and enhance market competitiveness.
- Showcase Participation: CEO Shaun Bagai and CFO Mark Voll will participate in the AGP Annual Healthcare Company Showcase on May 20, 2026, discussing the company's commercial progress and clinical research, which is expected to attract investor interest and enhance the company's visibility.
See More
